Lixte Historical Income Statement
| LIXT Stock | USD 3.14 0.12 3.68% |
Historical analysis of Lixte Biotechnology income statement accounts such as Selling General Administrative of 4 K can show how well Lixte Biotechnology Holdings performed in making a profits. Evaluating Lixte Biotechnology income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Lixte Biotechnology's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Lixte Biotechnology latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Lixte Biotechnology is a good buy for the upcoming year.
Lixte Biotechnology Net Income |
|
Lixte |
About Lixte Income Statement Analysis
Lixte Biotechnology Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Lixte Biotechnology shareholders. The income statement also shows Lixte investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Lixte Biotechnology Income Statement Chart
Lixte Biotechnology Holdings Income Statement is one of the three primary financial statements used for reporting Lixte's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Lixte Biotechnology revenue and expense. Lixte Biotechnology Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Lixte Biotechnology's Research Development is comparatively stable compared to the past year. Total Other Income Expense Net is likely to gain to 3,372 in 2024, despite the fact that Interest Expense is likely to grow to (15.4 K). Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Lixte Biotechnology. It is also known as Lixte Biotechnology overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from Lixte Biotechnology's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Lixte Biotechnology current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lixte Biotechnology Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest. At this time, Lixte Biotechnology's Research Development is comparatively stable compared to the past year. Total Other Income Expense Net is likely to gain to 3,372 in 2024, despite the fact that Interest Expense is likely to grow to (15.4 K).
Lixte Biotechnology income statement Correlations
Click cells to compare fundamentals
Lixte Biotechnology Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Lixte Biotechnology income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Expense | 49.7K | 3.7K | 7.4K | 8.9K | (16.2K) | (15.4K) | |
| Other Operating Expenses | 2.5M | 3.3M | 6.7M | 6.3M | 5.1M | 2.7M | |
| Operating Income | (2.5M) | (3.3M) | (6.7M) | (6.3M) | (5.1M) | (4.8M) | |
| Ebit | (2.5M) | (3.3M) | (6.7M) | (6.3M) | (5.1M) | (4.8M) | |
| Ebitda | (2.5M) | (3.3M) | (6.7M) | (6.3M) | (5.1M) | (4.8M) | |
| Total Operating Expenses | 2.5M | 3.3M | 6.7M | 6.3M | 5.1M | 2.7M | |
| Net Income | (2.4M) | (3.3M) | (6.7M) | (6.3M) | (5.1M) | (4.8M) | |
| Income Tax Expense | (49.7K) | (1.6K) | 6.8K | (7.8K) | (5.1K) | (4.8K) | |
| Depreciation And Amortization | 2.5K | 5.2K | 626.0 | 11.2K | 5.1K | 4.8K | |
| Selling General Administrative | 1.7M | 2.0M | 5.0M | 5.0M | 4.2K | 4.0K | |
| Research Development | 820.9K | 1.2M | 1.7M | 1.3M | 898.1K | 1.0M | |
| Income Before Tax | (2.4M) | (3.3M) | (6.7M) | (6.3M) | (5.1M) | (4.8M) | |
| Total Other Income Expense Net | 49.7K | 1.6K | (8.0K) | (1.1K) | 3.2K | 3.4K | |
| Net Income From Continuing Ops | (2.4M) | (3.3M) | (6.7M) | (6.3M) | (5.7M) | (6.0M) | |
| Net Income Applicable To Common Shares | (2.1M) | (2.4M) | (3.3M) | (6.7M) | (6.1M) | (5.8M) | |
| Net Interest Income | 49.7K | 1.6K | (6.8K) | 2.3K | 10.8K | 6.4K | |
| Interest Income | 49.7K | 5.2K | 626.0 | 11.2K | 20.5K | 12.9K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lixte Biotechnology Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Complementary Tools for Lixte Stock analysis
When running Lixte Biotechnology's price analysis, check to measure Lixte Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lixte Biotechnology is operating at the current time. Most of Lixte Biotechnology's value examination focuses on studying past and present price action to predict the probability of Lixte Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lixte Biotechnology's price. Additionally, you may evaluate how the addition of Lixte Biotechnology to your portfolios can decrease your overall portfolio volatility.
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges |
Is Lixte Biotechnology's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lixte Biotechnology. If investors know Lixte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lixte Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.66) | Return On Assets (0.64) | Return On Equity (1.11) |
The market value of Lixte Biotechnology is measured differently than its book value, which is the value of Lixte that is recorded on the company's balance sheet. Investors also form their own opinion of Lixte Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Lixte Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lixte Biotechnology's market value can be influenced by many factors that don't directly affect Lixte Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lixte Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lixte Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lixte Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.